Ali Amin

Dr. Ali Amin

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2016 in Human Pathology
Verified
Journal Article
Closed access
JLJianhong Li
Jianhong Li
SLShaolei Lu
Shaolei Lu
KLKara Lombardo
Kara Lombardo
RMRene Monahan
Rene Monahan
AAAli Amin
Ali Amin

1 February 2018 in Journal of Endourology
Verified
Journal Article
Closed access
JPJorge Francisco Pereira
Jorge Francisco Pereira
JRJoseph Renzulli
Joseph Renzulli
GPGyan Pareek
Gyan Pareek
DMDaniel Moreira
Daniel Moreira
RGRuiting Guo
Ruiting Guo
BGBoris Gershman
Boris Gershman
Introduction and Objectives: In recent years, there has been a shift to minimally invasive partial nephrectomy (MIPN) with the dissemination of robotic-assisted technology. However, contemporary data on the comparative morbidity of open PN and MIPN are lacking. We therefore evaluated the perioperative morbidity of MIPN and OPN using a contemporary national cohort. Methods: We identified 13,658 patients aged 18-89 who underwent PN from 2010-2015 in the National Surgical Quality Improvement Program (NSQIP) database, of whom 9,018 (66.0%) underwent MIPN. The associations of MIPN with 30-day morbidity were evaluated using logistic regression, adjusted for patient features. Results: Median age at surgery was 60 (IQR 51, 68) years. Overall, 30-day complications occurred in 6.7% of patients. Compared to OPN, MIPN was associated lower rates of 30-day complications (4.9% versus 10.1%, p<0.0001), perioperative blood transfusion (3.8% versus 12.5%, p<0.0001), prolonged hospitalization (5.6% vs 23.4%, p<0.0001), readmission (4.4% versus 7.8%, p<0.0001), reoperation (1.8% versus 3.2%, p<0.0001), and 30-day mortality (0.3% versus 0.6%, p=0.001). On multivariable analysis, MIPN was independently associated with a reduced risk of 30-day complications (OR 0.46,p<0.0001), perioperative blood transfusion (OR 0.27, p<0.0001), prolonged hospitalization (OR 0.19, p<0.0001), readmission (OR 0.59, p<0.0001), and reoperation (OR 0.57, p<0.0001). Post-operative complications occurred predominantly early after surgery, while hospital readmissions and reoperation occurred at a consistent rate. Conclusions: In this contemporary national cohort, MIPN was independently associated with reduced rates of 30-day complication, perioperative blood transfusion, prolonged hospitalization, hospital readmission, and reoperation, compared to OPN.

17 February 2021 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
YWYihong Wang
Yihong Wang
KSKamaljeet Singh
Kamaljeet Singh
DDDon Dizon
Don Dizon
TGTeresa Graves
Teresa Graves
AAAli Amin
Ali Amin
Evgeny YakirevichEvgeny Yakirevich
Evgeny Yakirevich

18 October 2022 in Cureus
Verified
Journal Article
Open access
AKAzadeh Khayyat
Azadeh Khayyat
MPMohammad Ali Esmaeil Pour
Mohammad Ali Esmaeil Pour
SMSeyedreza Mousavi
Seyedreza Mousavi
AKAmir-Reza Khalili-Toosi
Amir-Reza Khalili-Toosi
AAAli Amin
Ali Amin
Malignant melanoma (MM) of mucosal membranes (excluding anus and head-neck) is a rare but aggressive disease with poor outcomes. The knowledge of this tumor's development, etiology, and management is scarce, mainly due to the low case numbers. We presented eight cases and performed a comprehensive literature review on mucosal MM (between 1970 and 2020). We identified 47 manuscripts on 55 patients with primary mucosal MM (limited to urothelium and vagina) and reviewed demographics, tumor specifications (morphology, stage, etc.), management, and survival. We identified 10 manuscripts discussing treatment in 1595 mucosal and non-mucosal MM and extracted the data regarding the non-surgical treatment modalities of mucosal MM patients. In 63 cases, 48 tumors primarily occurred in the urothelium (urethra: 47, bladder: 1) and 15 in the vagina. Molecular studies in a subset of cases revealed alterations in c-KIT, NRAS, BRAF (non-V600E and V600E), TP53, and NF1. Fifty-three patients underwent surgery (with additional chemotherapy, immunotherapy, and radiotherapy in 19, eight, and eight patients, respectively). The outcome was available in 52 cases, showing 21 deaths, 10 without recurrence, two alive with disease, and five lost to follow-up. Shared genetic signatures in mucosal and skin MM suggest a similar development mechanism; however, unlike skin MM, there are less BRAF mutations and more PI3K/AKT/mTOR pathway alterations in mucosal MM. Prolonged chemotherapy (i.e., methotrexate) and immune-modulating agents (i.e., natalizumab) may be risk factors. The stage at diagnosis and proper surgical extirpation are keys to the prognosis and survival of patients.

4 July 2021 in Virchows Archiv
Verified
Journal Article
Closed access
PDF file
KHKoorosh Haghayeghi
Koorosh Haghayeghi
SLShaolei Lu
Shaolei Lu
AMAndres Matoso
Andres Matoso
SSStephen F. Schiff
Stephen F. Schiff
CMCatrina Mueller-Leonhard
Catrina Mueller-Leonhard
AAAli Amin
Ali Amin

2 April 2018 in Diagnostic Pathology
Verified
Journal Article
Open access
PDF file
CZChaohui Lisa Zhao
Chaohui Lisa Zhao
AAAli Amin
Ali Amin
YHYiang Hui
Yiang Hui
DYDongfang Yang
Dongfang Yang
WCWeibiao Cao
Weibiao Cao
The G protein-coupled bile acid receptor (TGR5) is a cell surface receptor which induces the production of intracellular cAMP and promotes epithelial-mesenchymal transition in gastric cancer cell lines. TGR5 is found in a wide variety of tissues including the kidney. However, the patterns of TGR5 expression have not been well characterized in physiologic kidney or renal neoplasms. We explore the expression of TGR5 in benign renal tissue and renal neoplasms and assess its utility as a diagnostic marker. Sixty-one renal cortical neoplasms from 2000 to 2014 were retrieved. TGR5 protein expression was examined by immunohistochemistry. TGR5 mRNA was also measured by real-time PCR. In normal renal tissue, TGR5 was strongly positive in collecting ducts, distal convoluted tubules and thin loop of Henle. Proximal convoluted tubules showed absent or focal weak staining. In clear cell renal cell carcinomas (RCCs), 25 of 27 cases (92%) were negative for TGR5 (p < 0.001). TGR5 mRNA was also significantly decreased in clear cell RCCs, suggesting that decreased TGR5 protein expression may be attributable to the downregulation of TGR5 mRNA in these tumors. All 11 papillary RCCs expressed TGR5 with 45% (5/11) exhibiting moderate to strong staining. All chromophobe RCCs and oncocytomas were positive for TGR5 with weak to moderate staining. TGR5 mRNA expression in these tumors was similar to normal kidney. All urothelial carcinomas of the renal pelvis strongly expressed TGR5 including a poorly differentiated urothelial carcinoma with sarcomatoid features. TGR5 is strongly expressed in collecting ducts, distal convoluted tubules and thin loop of Henle. TGR5 protein and mRNA expression were notably decreased in clear cell RCCs and may be helpful in differentiating these tumors from other RCCs.